1. Home
  2. TBPH vs HIVE Comparison

TBPH vs HIVE Comparison

Compare TBPH & HIVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • HIVE
  • Stock Information
  • Founded
  • TBPH 2013
  • HIVE 1987
  • Country
  • TBPH United States
  • HIVE Canada
  • Employees
  • TBPH N/A
  • HIVE N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • HIVE
  • Sector
  • TBPH Health Care
  • HIVE
  • Exchange
  • TBPH Nasdaq
  • HIVE Nasdaq
  • Market Cap
  • TBPH 418.7M
  • HIVE 438.0M
  • IPO Year
  • TBPH N/A
  • HIVE N/A
  • Fundamental
  • Price
  • TBPH $9.69
  • HIVE $4.14
  • Analyst Decision
  • TBPH Buy
  • HIVE Strong Buy
  • Analyst Count
  • TBPH 4
  • HIVE 5
  • Target Price
  • TBPH $13.75
  • HIVE $7.40
  • AVG Volume (30 Days)
  • TBPH 191.3K
  • HIVE 6.1M
  • Earning Date
  • TBPH 11-12-2024
  • HIVE 11-13-2024
  • Dividend Yield
  • TBPH N/A
  • HIVE N/A
  • EPS Growth
  • TBPH N/A
  • HIVE N/A
  • EPS
  • TBPH N/A
  • HIVE N/A
  • Revenue
  • TBPH $63,192,000.00
  • HIVE $123,022,000.00
  • Revenue This Year
  • TBPH $6.93
  • HIVE N/A
  • Revenue Next Year
  • TBPH $45.31
  • HIVE N/A
  • P/E Ratio
  • TBPH N/A
  • HIVE N/A
  • Revenue Growth
  • TBPH 15.93
  • HIVE 55.97
  • 52 Week Low
  • TBPH $7.44
  • HIVE $2.18
  • 52 Week High
  • TBPH $11.71
  • HIVE $5.74
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 70.66
  • HIVE 51.76
  • Support Level
  • TBPH $9.38
  • HIVE $4.09
  • Resistance Level
  • TBPH $10.10
  • HIVE $4.58
  • Average True Range (ATR)
  • TBPH 0.32
  • HIVE 0.41
  • MACD
  • TBPH 0.11
  • HIVE -0.06
  • Stochastic Oscillator
  • TBPH 83.26
  • HIVE 37.32

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About HIVE HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.

Share on Social Networks: